|
Abstract To observe the expression and the correlation of serum interleukin-17 (IL-17), interleukin-23 (IL-23), and brain-derived neurotrophic factor (BDNF) of the patients with endometriosis (EMT). Methods: A total of 104 patients with EMT were selected in group A between June 2019 and January 2021. According to R-AFS staging, the patients in group A were divided into 13 cases with stage I in group A1, 27 cases with stage II in group A2, 39 cases with stage III in group A3, and 25 cases with stage IV in group A4. In addition, 80 healthy women of childbearing age were selected in the control group during the same period. The serum levels of IL-17, IL-23, and BDNF of the patients in the five groups were detected and compared. The correlation between R-AFS staging and IL-17, IL-23, and BDNF levels was analyzed by linear regression. Results: The levels of serum IL-17, IL-23, and BDNF of the patients in group A were significant higher than those of the patients in the control group, and with the increasing of R-AFS stage, the levels of serum IL-17, IL-23, and BDNF of the patients in group A had increased significantly (P＜0.05).The R-AFSR staging of the patients in group A was positively correlated with their levels of IL-17, IL-23, and BDNF (r=0.906, 0.917, 0.695, P＜0.05). There were positive correlations among the IL-17 level, IL-23 level, and BDNF level (P＜0.05). Binary logistic regression analysis showed that the levels of IL-17, IL-23, and BDNF, and their interactions were all the independent risk factors of high stage R-AFS of the patients with EMT (P＜0.05). The expressions of the IL-17, IL-23, and BDNF levels of the patients with EMT are high, and which increase with the increasing of R-AFS staging. The serum IL-17, IL-23, and BDNF levels may affect the progression of EMT by synergistic effect each other.
|
